Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials

Background In randomised controlled trials, as-needed inhaled corticosteroid (ICS)-formoterol reliever therapy reduces severe exacerbation risk compared with maintenance ICS plus short-acting beta2-agonist (SABA) reliever in adolescent and adult asthma, but results in slightly worse control of asthma symptoms, as measured by mean Asthma Control Questionnaire-5 (ACQ-5) score.Objective To assess the levels and changes in asthma control for as-needed budesonide–formoterol versus maintenance budesonide plus SABA in post hoc analyses from the Novel START and PRACTICAL clinical trials.Methods The nu... Mehr ...

Verfasser: James Fingleton
Mark Weatherall
Richard Beasley
Irene Braithwaite
Ian Pavord
Jenny Sparks
Lee Hatter
Helen K Reddel
Robert J Hancox
Mark Holliday
Andrew Corin
Daniela Hall
Claire Houghton
Saras Mane
John Martindale
Karen Oldfield
Donah Sabbagh
Alexandra Vohlidkova
Alberto Papi
Allie Eathorne
Pepa Bruce
Dokumenttyp: Artikel
Erscheinungsdatum: 2022
Reihe/Periodikum: BMJ Open Respiratory Research, Vol 9, Iss 1 (2022)
Verlag/Hrsg.: BMJ Publishing Group
Schlagwörter: Medicine / R / Diseases of the respiratory system / RC705-779
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-27249011
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.1136/bmjresp-2022-001271